Journal
RESPIRATORY RESEARCH
Volume 16, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s12931-015-0267-6
Keywords
-
Categories
Funding
- GlaxoSmithKline
- National Institute for Health Research [NF-SI-0510-10249, NF-SI-0513-10040] Funding Source: researchfish
Ask authors/readers for more resources
Background: New treatments need to be evaluated in real-world clinical practice to account for co-morbidities, adherence and polypharmacy. Methods: Patients with chronic obstructive pulmonary disease (COPD), >= 40 years old, with exacerbation in the previous 3 years are randomised 1:1 to once-daily fluticasone furoate 100 mu g/vilanterol 25 mu g in a novel dry-powder inhaler versus continuing their existing therapy. The primary endpoint is the mean annual rate of COPD exacerbations; an electronic medical record allows real-time collection and monitoring of endpoint and safety data. Conclusions: The Salford Lung Study is the world's first pragmatic randomised controlled trial of a pre-licensed medication in COPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available